SA
Log In
INSM
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
35 analysts·High coverage
73
Score
33 Buy (94%)1 Hold (3%)1 Sell (3%)
Rating Breakdown
Strong Buy
00%
Buy
3394%
Hold
13%
Sell
13%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$166.00
+18.6%
Consensus
$213.50
+52.5%
Bull
$269.00
+92.1%
12-Month Target Range35 analysts
$166.00$213.50$269.00
Current $140.01Consensus
Current Price
$140.01
Upside to Consensus
$73.49

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+66.03%
EPS—
FY2028
Rev+40.21%
EPS+270.23%
FY2029
Rev+31.85%
EPS+100.16%

Earnings Surprises

Recent Analyst Actions

Apr 16, 2026Guggenheim
Insmed price target raised to $230 from $227 at Guggenheim
Target:$230.00
+56.7%from $146.74
Apr 14, 2026RBC Capital
Insmed price target raised to $216 from $212 at RBC Capital
Target:$216.00
+42.9%from $151.14
Apr 10, 2026Raymond James
Insmed initiated with an Outperform at Raymond James
Target:$200.00
+28.4%from $155.80
Apr 8, 2026Mizuho Securities
Insmed price target lowered to $202 from $206 at Mizuho
Target:$202.00
+26.1%from $160.18
Mar 26, 2026H.C. Wainwright
Insmed price target raised to $245 from $230 at H.C. Wainwright
Target:$245.00
+66.0%from $147.60
Feb 24, 2026Mizuho Securities
Insmed price target lowered to $204 from $211 at Mizuho
Target:$204.00
+28.3%from $159.03
Feb 20, 2026Morgan Stanley
Insmed price target raised to $166 from $162 at Morgan Stanley
Target:$166.00
+4.5%from $158.80
Feb 20, 2026Wells Fargo
Insmed price target lowered to $208 from $234 at Wells Fargo
Target:$208.00
+29.2%from $161.00
Feb 19, 2026Stifel Nicolaus
Insmed price target lowered to $205 from $212 at Stifel
Target:$205.00
+28.2%from $159.88
Feb 19, 2026Mizuho Securities
Insmed price target lowered to $211 from $212 at Mizuho
Target:$211.00
+39.6%from $151.11
Jan 27, 2026Barclays
Insmed initiated with an Overweight at Barclays
Target:$231.00
+42.0%from $162.64
Jan 22, 2026Roth Capital
Insmed initiated with a Buy at Roth Capital
Target:$212.00
+32.2%from $160.39
Jan 21, 2026RBC Capital
Insmed price target raised to $200 from $197 at RBC Capital
Target:$200.00
+22.3%from $163.51
Jan 12, 2026Truist Financial
Truist on Insmed (INSM): Brinsupri Launch Outpacing Most Bullish Expectations
Target:$205.00
+23.3%from $166.25
Jan 8, 2026Morgan Stanley
Insmed price target lowered to $157 from $158 at Morgan Stanley
Target:$157.00
-10.8%from $176.00
Jan 6, 2026UBS
Insmed price target lowered to $215 from $223 at UBS
Target:$215.00
+24.0%from $173.34
Dec 19, 2025Truist Financial
Insmed assumed with a Buy at Truist
Target:$202.00
+21.3%from $166.55
Dec 18, 2025H.C. Wainwright
Insmed price target lowered to $230 from $240 at H.C. Wainwright
Target:$230.00
+38.6%from $165.99
Dec 18, 2025Cowen & Co.
Insmed price target lowered to $241 from $269 at TD Cowen
Target:$241.00
+43.9%from $167.53
Dec 18, 2025Mizuho Securities
Insmed (INSM) PT Lowered to $212 at Mizuho, 'We're Buyers on Weakness'
Target:$212.00
+26.4%from $167.71
Dec 18, 2025Guggenheim
Insmed price target lowered to $221 from $230 at Guggenheim
Target:$221.00
+11.4%from $198.46
Dec 18, 2025Wedbush
Insmed (INSM) PT Lowered to $203 at BofA Securities
Target:$203.00
+21.4%from $167.22
Dec 18, 2025RBC Capital
Insmed (INSM) PT Lowered to $195 at RBC Capital
Target:$195.00
-1.7%from $198.46
Dec 18, 2025Wells Fargo
Insmed (INSM) PT Lowered to $195 at Leerink Partners
Target:$195.00
-1.7%from $198.46
Dec 18, 2025Wolfe Research
Insmed (INSM) PT Lowered to $167 at Wolfe Research
Target:$167.00
-15.9%from $198.46

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance